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a r t i c l e i n f o a b s t r a c t 
Quality improvement programs and clinical trial research experienced disruption due to the 
coronavirus disease 2019 (COVID-19) pandemic. Vascular registries showed an immediate 
impact with significant declines in second-quarter vascular procedure volumes witnessed 
across Europe and the United States. To better understand the magnitude and impact of 
the pandemic, organizations and study groups sent grass roots surveys to vascular spe- 
cialists for needs assessment. Several vascular registries responded quickly by insertion of 
COVID-19 variables into their data collection forms. More than 80% of clinical trials have 
been reported delayed or not started due to factors that included loss of enrollment from 
patient concerns or mandated institutional shutdowns, weighing the risk of trial participa- 
tion on patient safety. Preliminary data of patients undergoing vascular surgery with active 
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COVID-19 infection show inferior outcomes (morbidity) and increased mortality. Disease- 
specific vascular surgery study collaboratives about COVID-19 were created for the desire 
to study the disease in a more focused manner than possible through registry outcomes. 
This review describes the pandemic effect on multiple VASCUNET registries including Ger- 
many (GermanVasc), Sweden (SwedVasc), United Kingdom (UK National Vascular Registry), 
Australia and New Zealand (bi-national Australasian Vascular Audit), as well as the United 
States (Society for Vascular Surgery Vascular Quality Initiative). We will highlight the con- 
tinued collaboration of VASCUNET with the Vascular Quality Initiative in the International 
Consortium of Vascular Registries as part of the Medical Device Epidemiology Network co- 
ordinated registry network. Vascular registries must remain flexible and responsive to new 
and future real-world problems affecting vascular patients. 











































































After the global shutdown in March of 2020, quality improve-
ment programs and clinical trial research experienced dis-
ruption due to the coronavirus disease 2019 (COVID-19) pan-
demic. Vascular registries showed an immediate impact with
significant reductions in second-quarter vascular procedure
volumes witnessed across Europe and the United States [1–3] .
To better understand the magnitude and impact of the pan-
demic, organizations and study groups sent grass roots sur-
veys to vascular specialists for needs assessment. Several vas-
cular registries responded quickly by insertion of COVID-19
variables into their data collection forms. More than 80% of
clinical trials have been reported delayed or not started due
to factors that included loss of enrollment from patient con-
cerns or mandated institutional shutdowns, weighing the risk
of trial participation on patient safety [4–6] . Other reasons for
clinical trial interruption included delayed ethical and regu-
latory approval of research projects and favored by a priori-
tization of COVID-19 research. Furthermore, the urgent need
to redeploy staff to clinical areas resulted in directives to sus-
pend data collection in National Clinical Audits [7] . 
This review highlights the pandemic’s effect on multi-
ple VASCUNET registries including Germany (GermanVasc),
Sweden (SwedVasc), United Kingdom (UK National Vascular
Registry [NVR]), Australia and New Zealand (bi-national Aus-
tralasian Vascular Audit), as well as the United States (Society
for Vascular Surgery Vascular Quality Initiative [VQI]). We will
discuss changes made in registry data capture, highlighting
concordance of variables and definitions across registries. A
preliminary analysis of COVID-19–related data from the NVR
provides an early assessment of outcomes. Registry variables
related to COVID-19 emphasize the need for flexibility with
ongoing challenges using real-world data in real time. Collab-
oration efforts by coordinated registry networks between VAS-
CUNET and VQI and their integration with the International
Consortium of Vascular Registries (ICVR) will be addressed. 
The pandemic has also spurred rapid development of
prospective patient cohort analyses, calling to attention re-
search efforts by the Vascular and Endovascular Research Net-
work (VERN) and the Vascular Surgery COVID-19 Collaborative
(VASCC) and the challenges in “big data.” In addition, barriers
to registry modifications and continued clinical trial research
in the midst of a pandemic will be reviewed. 2. Pathogenesis 
The severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) responsible for the new coronavirus disease, COVID-
19, infection demonstrates increased affinity for human
angiotensin-converting enzyme 2 receptors in respiratory
epithelium through spike protein modifications, increasing
transmissibility during a previous SARS-CoV outbreak in 2002
[8] . Viral-induced activation of coagulation pathways and cy-
tokine damage to vascular endothelium secondary to COVID-
19 infection provoke a prothrombotic state affecting both mi-
crovascular and macrovascular arterial and venous systems
[9] . Occult strokes, venous thromboses, pulmonary throm-
boembolism, Kawasaki-like syndrome in children and COVID
toes are just some of the presentations seen from the novel
coronavirus [10–12] . 
3. Vascular management decisions of 
COVID-19 infection 
The global pandemic caused by SAR-CoV-2 forced the vascular
community to re-assess the management of elective vascular
disease and learn how to treat the vascular complications of
COVID-19 infection. In the absence of published literature or
evidence-based data about COVID-19, vascular surgeons had
to assess the risk benefit of both routine and emergency care
and evaluate each in the context of local community infec-
tion rates and available hospital resources. Rapidly developed
guidelines from the American College of Surgeons (tiers 1 to 3)
and the Vascular Activity Condition (VASCCON) became a use-
ful aid for decision-making triage, as seen in Table 1 [13 ,14] . 
The implications of delaying treatment for routine vascu-
lar care and the rate of progression of disease are often not
well defined, although the consequences are. Delays in treat-
ment are variable for an asymptomatic carotid stenosis versus
an asymptomatic > 6.5 cm abdominal aortic aneurysm (AAA)
or a patient with an infected dialysis catheter in need of an-
gioaccess [15] . 
Vascular registries are primarily procedural-based and not
designed to evaluate delayed care or medical management.
VQI recently released a Medical Management registry to
collect data on medically managed patients with AAA, carotid
stenosis, and lower extremity occlusive disease, but has
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Table 1 – Types of surgical activities and levels of surgical activity condition and vascular surgery activity condition. 
SURGCON level Type of surgical activity VASCCON 
5 Evidence-based surgical practice Clinical practice guideline directed care of AAA, CAS, PAD 
4 Limitations on nonemergency surgery Booked cases limited to AAA > 6 cm, symptomatic CAS, CLTI 
3 Severe limitations on nonemergency surgery Booked cases limited to AAA > 8 cm, symptomatic CAS, severe 
CLTI 
2 Emergency surgery only No booked cases, emergency cases include ruptured AAA, 
acute limb ischemia 
1 No surgical activity No emergency or booked surgery (patients with ruptured AAA 
are palliated) 
From Forbes TL. Vascular surgery activity condition is a common language for uncommon times. J Vasc Surg 2020;72:391–2 [14] , adapted with 
permission. 
Abbreviations: AAA, abdominal aortic aneurysm; CAS, carotid artery stenosis; CLTI, chronic limb-threatening ischemia; PAD, peripheral artery 













































































limited enrollment. Procedural registries can analyze the
impact of comorbidities if the pertinent variables are in the
collection form. New and unique variables must be added
to the registries in order to provide data for analysis of new
conditions. 
The earliest insight into changes in practice patterns
comes from surveys conducted with vascular surgeons [16] .
A survey by Aziz et al [17] with US vascular surgeons showed
that most noticed a decrease in clinic referrals, emergency de-
partment consults, and overall case volumes. Similarly, a sur-
vey by the COVER (COVID-19 Vascular Service) Study Collabo-
rative showed that globally, there was a trend in the reduction
in all peripheral vascular surgery, including carotid, aortic, and
lower extremity arterial operations [18] . These surveys also in-
dicate that many patients with vascular disease delayed seek-
ing medical attention and experienced adverse consequences.
News media outlets reported that a number of patients with
heart attack and stroke avoided emergency departments or
appropriate medical care, presenting late or dying at home
[19] . 
Similar suppositions can be made for patients with AAAs,
carotid artery stenosis, and severe peripheral arterial disease
[20] . 
A review of current literature showed that COVID-19 in-
fection is associated with an acquired hypercoagulable state.
Nypaver et al [21] reviewed seven patients with COVID-19
who presented with stroke and concluded that COVID-19 is
associated with increased thrombus formation in extracra-
nial carotid arteries. Ilonzo et al [22] described thrombotic
complications of 21 patients who were severely ill during the
height of the pandemic in New York City. Overall mortality was
28.6% with more than three-fourths presenting with acute ar-
terial thrombosis and critical ischemia. Increased mortality in
patients with COVID-19 complicated by venous thromboem-
bolism has also been reported [23] . 
Patients with COVID-19 can have a myriad of presentations
in vascular beds, and registry databases will have to be flexible
to respond rapidly to a changing clinical environment. There
are important unresolved questions, such as when elective
operations can be safely performed during a COVID-19 surge,
which “elective” operations, for example, > 6.5-cm AAA should
be prioritized in the presence of restricted resources, and how
long does the prothrombotic condition last after COVID-19 in-fection before it is safe to proceed with elective operations,
such as treatment for claudication or varicose veins. Broad-
ening the scope of databases to include new variables in a
timely fashion will have the potential to address these im-
portant clinical dilemmas. Registry data may provide better
understanding should another pandemic occur in the future. 
4. Registry additions of COVID-19 variables 
Determining the magnitude of the novel coronavirus infec-
tion on vascular disease management requires collecting new
preoperative and postoperative clinical variables. Shortly af-
ter the onset of the pandemic, VQI (regional) and VERN (in-
ternational) surveyed their membership. It was evident early
on that many COVID-19 risk factors are also highly prevalent
in vascular surgical patients, including advanced age, male
sex, smoking, obesity, coronary artery disease, hypertension,
chronic pulmonary disease, chronic renal disease, diabetes,
and malignancy. Given the lack of knowledge about COVID-19,
many vascular registries independently responded with rapid
insertion of COVID-19–related variables into their data collec-
tion forms for monitoring impact. Multicenter study collabo-
ratives were formed to better understand COVID-19’s impact
on patients with vascular disease (VASCC and COVER). The
additional COVID-19–related variables are listed in Table 2 .
As these variables were developed independently, there were
some minor differences noted across registries. COVID-19 in-
fection status, procedure delays, disease worsening, and mor-
tality were the most commonly chosen data fields. Timing of
COVID-19 variable insertion into registry databases occurred
as quickly as mid-April 2020 (UK NVR, SwedVasc) to early
September 2020 (VQI). The speed of registry revision was re-
markable, given additional variable insertion typically takes a
minimum of 12 to 18 months. The NVR COVID-19 data fields
were initially added to the peripheral artery disease and AAA
datasets and went live in April 2020, and new variables were
added to the carotid data set in June 2020 [24] . 
The addition of COVID-19 data fields was variable in other
VASCUNET registries. The GermanVasc registry retrospec-
tively surveyed COVID-19–related variables on a voluntary
basis at participating centers. The Australasian Vascular
Audit has not yet elected to collect COVID-19 data. Of note,
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Table 2 – COVID-19–related variables per registry/study collaborative. 
Variable SwedVasc a US VQI b UK NVR c COVER d VASCC e 
Registry origin 1987 2011 2005 NA NA 
COVID insertion date April 2020 September 2020 April 2020 April 2020 April 2020 
At procedure 
Exposure history + + + + + 
Test result at procedure + + + + + 
Symptom status – + + + + 
Procedure delay + + + + + 
Disease worsening – + + – –
Adverse events 
Procedure change – – + + + 
Conversion – – + + + 
COVID reoperation – – – + + 
COVID graft occlusion – – – + + 
COVID DVT/VTE – – – + + 
COVID mortality at follow-up + – – + + 
COVID pneumonia – – + + + 
COVID status + + – + + 
Re-admission – – – + + 
Vaccination – – – – –
Adverse events + – – + + 
Abbreviations: COVER, COVID-19 Vascular Service; COVID-19, coronavirus disease 2019; DVT, deep venous thrombosis; NVR, National Vascular 
Registry; VASCC, Vascular Surgery COVID-19 Collaborative; VTE, venous thromboembolism; VQI, Vascular Quality Initiative. 
a SwedVasc captures procedure data for carotid, abdominal aortic aneurysm (AAA), peripheral artery disease (PAD)-peripheral vascular 
intervention (PVI), venous, and trauma. Follow-up is at 30 days and 1 year. Lifelong surveillance possible via national identifier. 
b US VQI captures procedure data for 14 registries: carotid endarterectomy (CEA), carotid artery stenting (CAS), thoracic endovascular 
aneurysm repair (TEVAR)/complex endovascular aneurysm repair, endovascular aneurysm repair, supra- and infrainguinal bypass, open aor- 
tic, lower extremity bypass, PVI, amputation, inferior vena cava filter, varicose vein, venous stent, and hemodialysis. Follow-up is at 30 days 
and 1 year (9 to 21 months). 
c UK NVR captures data for AAA, CEA, PVI, lower extremity bypass, and amputation. Follow-up is at 30 days. 
d COVER is an international multicenter study collaborative project collecting outcomes of all major vascular surgery and procedures dur- 
ing COVID pandemic at 30 days, 6 months, and 12 months. It is led by the Vascular and Endovascular Research Network collaborative and 
sponsored by the University Hospital of Coventry and Warwickshire. 
e VASCC is an international survey collaborative capturing procedure data on aortic, carotid, peripheral, venous, and hemodialysis focusing 












































no registry or study collaborative is currently capturing data
on vaccination status. This apparent oversight reflects more
on the speed with which variable insertion and study collab-
oratives were developed before widespread vaccination and
the burdensome nature of registry modification. 
In addition, in April of 2020, the World Health Organization
and Family of International Classification issued how a con-
firmed SARS-CoV-2 infection must be coded to generate reli-
able administrative data in the future. This has since received
periodic updates as COVID-19 information has progressed [25] .
5. Registry volumes 
As mentioned previously, most registries experienced signif-
icant initial procedural volume decline at the beginning of
the pandemic in March 2020. Similar to VQI reporting, initial
UK NVR analysis confirmed declines in major vascular proce-
dures in AAA (12%), carotid endarterectomy (38%), and lower
limb bypass (38%) during April of 2020 [26] . By July 2020, elec-
tive volumes of AAA and CEA had returned to approximately
80% of prepandemic levels ( Fig. 1 ). Table 3 demonstrates year-
end recovery of 2020 procedure volumes to approximately 85%
of 2018 and 2019. This value may be a slight underestimate,as some registries could not provide complete year-end to-
tals. Notably, Sweden (which avoided formal shutdown of the
society as part of its COVID-19 response) and Australia/New
Zealand (where COVID-19 rates remained exceptionally lower
than other countries) are two exceptions where restrictive
measures were not placed on medical practice. When com-
pared to 2019 values, carotid, aortic, and peripheral arterial
procedures (range, 84% to 104%) were impacted less than vari-
cose vein, inferior vena cava filter and venous stenting (range,
66% to 85%). We were unable to determine whether COVID-19
caused a notable shift to more endovascular approaches over
open procedures at this high-level analysis, as survey reports
suggest. Individual-center reports indicate an endovascular-
first approach likely reflects competing interests on surge ca-
pacity for intensive care unit resources from other services
and risk of staff exposure to the virus [27] . Ongoing assess-
ment will be necessary to determine whether this perception
is real. Interestingly, in Germany (which implemented exten-
sive restrictions of public life and health services in March of
2020), a decline of registry volumes and emergent admissions
in administrative registries was observed, and no change in
management was apparent. Elective (asymptomatic) to non-
elective (symptomatic or emergent) volume ratios for aortic
and infrainguinal bypass in 2020 declined from those in 2018
32 S e m i n a r s  i n  Va s c u l a r  S u r g e r y  3 4  ( 2 0 2 1 )  2 8 – 3 6  
Fig. 1 – (A) UK National Vascular Registry (NVR) and US Vascular Quality Initiative (VQI) comparison: carotid endarterectomy. 
Weekly number of carotid endarterectomies for first 30 weeks of 2020. Red line denotes week of March 15th. (B) UK NVR and 
US VQI comparison: infrarenal abdominal aortic aneurysm (AAA) repair. Weekly number of AAA repairs for first 30 weeks of 
2020. The red line denotes the week of March 15th. NVR data include elective infrarenal AAA repairs. VQI data include all 




















































and 2019 (range, 8% to 53%; median, 14%), as would be ex-
pected given the restrictions placed on elective surgery in
most countries. This resulted in a higher percentage of non-
elective cases (symptomatic) overall in 2020, reflecting fewer
elective operations. Elective to nonelective ratios for carotid
and venous categories were not included in Table 3 , given
variable definitions and management within these categories.
Differences between registries on asymptomatic carotid inter-
ventions performed in the US VQI compared to European reg-
istries has been reported previously [28] . 
Factors likely contributing to this reduction include pa-
tient (fear, reluctance to seek care), surgeon (change in AAA
size threshold, delay in intervention), resources (bed capacity,
staffing), and governance (national/state directives) [26 ,29] . As
local restrictions were lifted by July to August of 2020, proce-
dure volumes gradually approached previous annualized vol-
umes. It remains unclear whether long-term consequences
will result in increased adverse patient outcomes. The pan-
demic provides a unique opportunity to study the natural
history of medically managed AAA and symptomatic carotid
stenosis. NVR reporting on emergency vascular procedures
at the beginning of the pandemic showed declines in rup-
tured AAA (76%) and major lower limb amputation (83%).
This is quite surprising, as these medical catastrophes or ur-
gent operations would not be expected to be significantly
impacted. This will require further trend analysis from both
registry data and study collaboratives, such as VASCC and
COVER. 6. COVID-19 disease-specific collaboratives 
In addition to registry data collection, COVID-19 study col-
laboratives seeking global cooperation and data sharing also
emerged in March of 2020. The VASCC is a combined interna-
tional effort custom-designed for prospective data collection
on the impact of vascular surgical care delays and perioper-
ative management of thrombotic complications in patients
with COVID-19 infection. VASCC is organized and led by Max
Wohlauer, University of Colorado, and Robert Cuff, Michigan
State University. De-identified patient information is housed
in a REDCap registry at the University of Colorado Anschutz
Medical Campus. As of March 2021, 171 centers from 40
countries are involved, including multiple centers from VQI
and VASCUNET. VQI and VASCC worked together on harmo-
nization of variables and definitions to optimize future data
aggregation and collaboration. VASCC has partnered with CPC
Clinical Research in Aurora, CO and Fondazione Policlinico
Gemelli Istituto di Ricovero e Cura a Carattere Scientifico in
Rome, Italy, to strengthen the international collaboration [30] .
VERN also launched the COVER study, sponsored by the
Vascular Society of Great Britain and Ireland, a prospective
cohort study with data contributed from 251 centers in 53
countries under the direction of Sandip Nandra, Newcastle
University and Ruth Benson, University Hospital Coventry
[18] . The study was conceived as a three-tier project, fo-
cusing on the following different aspects of vascular care:
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Table 3 – Registry volumes. 





Case volume Volume change 
from 2019, % b 
Elective to 
nonelective ratio c 
Mean no. of 
cases per center 
Carotid d 
AU 118 1,934 1,793 1,673 93.3 14 
NZ 14 303 296 280 94.6 20 
SE 20 788 795 778 97.8 39 
US 345 21,267 26,435 22,442 84.9 65 
Aortic e 
AU 114 2,373 2,293 2,034 88.7 2.74 18 
NZ 14 459 507 476 93.9 1.93 34 
SE 28 1,292 1,339 1,326 99.0 2.75 47 
US 235 9,394 9,927 8,363 84.2 4.06 36 
Infrainguinal 
bypass f 
AU 111 1,423 1,428 1,278 89.5 1.07 12 
NZ 13 293 305 301 98.7 1.12 23 
SE 28 1,224 1,134 1,041 91.8 1.21 37 
US 182 5,996 6,090 5,758 94.5 3.29 32 
Venous g 
AU 165 6,235 5,639 3,741 66.3 23 
NZ 14 345 365 250 68.5 18 
SE 34 10,022 11,317 9,566 84.5 281 
US 60 8,395 9,548 7,390 77.4 123 
Abbreviations: AU, Australia; NZ, New Zealand; SE, Sweden, US, United States (Vascular Quality Initiative). 
a No. of centers participating in all 3 years for carotid, aortic, infrainguinal bypass, and venous. 
b 2020 volumes compared to 2019 (using 2019 as denominator). 
c Ratio of elective (asymptomatic/routine) procedures divided by nonelective (urgent/emergent) procedures performed in 2020. Symptomatic 
cases are counted as a nonelective procedure. 
d Carotid procedures include both carotid endarterectomy/carotid artery stenting. 
e Aortic includes both endovascular aneurysm repair and open procedures for infrarenal aortic procedures. 
f Infrainguinal bypass includes lower extremity bypass only. 











































quantification, analysis, and demonstration of changes to
global vascular activity during the course of 2020; in-hospital
outcomes following common vascular procedures with
subsequent 6- and 12-month follow-up; and changes in
the management of consecutive patients presenting with
common vascular conditions during the pandemic, includ-
ing medium- and long-term follow-up. Key COVER findings
documented a significant decrease in usual vascular activity,
transitioning changes of care to telemedicine, and the avoid-
ance of surgery in presentations other than only the largest
aneurysms or most severe arterial occlusive disease. The
study has also shown that globally, restricting treatment to
more advanced clinical presentations was associated with a
marked increase in-hospital overall vascular service mortality
at 11%, despite a modest suspected or confirmed COVID-19
infection rate (4%) [18] . 
As seen in Table 2 , study collaboratives can provide a more
comprehensive COVID-19 variable data collection than exist-
ing registries (which require modification) given the enhanced
flexibility of creating de novo data elements specifically tar-
geted at COVID-19. In addition, the study collaboratives focus
on the disease rather than the procedure, thereby expand-
ing the inclusion criteria for data collection. In contrast to
registries that are procedure-based, study collaboratives are
disease-specific and focused. A patient succumbing to an ad- 
verse event (ie, disabling stroke or ruptured aneurysm) before
receiving an operation will not be included in a procedure-
based registry, but would be included into a study collabora-
tive given the inclusion criteria. 
However, both VASCC and COVER are limited by voluntary
participating centers, in contrast to population-based vascu-
lar surgical registries with administrative data infrastructure.
Procedure-based registries and study collaboratives can moni-
tor the effects of the pandemic on the overall vascular surgical
population from different and broader perspectives. It will be
important to cross-link registry data (having established long-
term outcomes) with the robust data produced in disease-
specific study collaboratives to provide a more comprehensive
analysis of the COVID-19 pandemic’s effect on vascular dis-
ease management and outcomes. The US VQI has 65 centers
participating in VASCC, with plans to coordinate data collec-
tion and long-term follow-up. 
7. Registry outcomes 
Most vascular registries collect data on short-term outcomes
after procedures, recording lengths of stay, complications, and
death within the primary hospitalization or 30 days from oper-
ation. Initial data from the COVER study suggest that vascular





































































































surgery in vulnerable patients may have a very high risk for
mortality and morbidity [29] . Although the UK NVR COVID-
positive rates were only 2.2% on the vascular service (April
through July 2020), mortality in patients with AAA and pe-
ripheral artery disease and a positive COVID-19 diagnosis was
6.1%, compared to 2.2% in those who were COVID-negative.
This was independent of respiratory complications defined
as pneumonia, ventilator support > 48 hours, adult respi-
ratory distress syndrome or pulmonary embolism. Mortality
of COVID-positive patients experiencing respiratory compli-
cations rose to 38.2% compared to those who were COVID-
negative at 27.9% [26] . 
Registries may use cross-matching of data linkage with ad-
ministrative databases or other health care consortia to deter-
mine long-term survival and reintervention. Data accumula-
tion may have a lag time of 1 to 2 years, delaying assessment
of procedural outcomes until this process is complete. Use of
disease-specific study collaboratives and registry linkage to
administrative databases will be required to understand the
long-term consequences of COVID-19 infection. 
Table 3 indicates a variable effect of the pandemic on over-
all vascular surgical operation volumes during 2020 ranging
from 66% to 99% compared to the previous year. The catch-up
effect for vascular surgical interventions after reduced activ-
ity during a shutdown or a local viral outbreak of COVID in-
fection will require further analysis. The downstream effect
of the pandemic on more selective patient treatment or in-
creased endovascular procedures to reduce length of hospital
stay or need for intensive care also requires further detailed
assessment. 
8. COVID-19 impact on clinical trial research 
The importance of scientific research during the COVID-19
pandemic has been highlighted by the dramatic advances
made in both the therapeutic management of and the de-
velopment of vaccines against COVID-19. Vascular surgeons
recognized the importance of studying the impact of COVID-
19 on vascular patients early in the pandemic and initiatives
such as VASCC and COVER are testament to this [31] . How-
ever, there is no doubt that COVID-19 has also impacted exist-
ing vascular trials. Academicians, research nurses, and other
research staff were frequently redeployed to support front-
line hospital services at the start of the pandemic, and this
resulted in some important trials being halted [32] . The UK-
Compass study, a multicenter study on the management of
juxtarenal AAAs temporarily paused recruitment in March
2020 and restarted in July 2020 [33] . The reluctance of con-
tinuing active trials or initiation of new trials by researchers,
manufacturers, and patients must be tempered with concern
about undergoing procedures with the confounding impact
of COVID-19 on outcomes (eg, stent thrombosis or increased
mortality) during the pandemic. 
There have been pandemic-influenced positive develop-
ments for both registries and research. In the UK, NHS Dig-
ital has rapidly developed a Trusted Research Environment
that links electronic health records. This initiative led by the
Cardiovascular Disease UK Consortium has linked electronic
health records from primary care, hospital episodes, deathregistries and National Clinical Audits with COVID-19 lab-
oratory tests and COVID-19 vaccination data. These linked
datasets are already producing important information on the
impacts of COVID-19 on cardiovascular disease [34] . 
9. VASCUNET, VQI, and ICVR 
The ICVR was formed as a Medical Device Epidemiology Net-
work (MDEpiNet) coordinated registry network by collabora-
tion of VASCUNET and VQI beginning in 2014, with active par-
ticipation of representatives from the registries and US Food
and Drug Administration. MDEpiNet ( www.MDEpiNet.net ) is
a public–private partnership with international chapters in
five countries that brings together health care profession-
als, industry representatives, patient groups, insurance pay-
ers, and governmental agencies to provide a network capable
of long-term medical device evaluation and ongoing surveil-
lance. The relationship of MDEpiNet to the ICVR allows for in-
ternational quality improvement and eventually device eval-
uation and surveillance. VASCUNET has grown to include 26
regional and national registries in European, South American,
and Australasian countries who actively work together to har-
monize their registry data collection and pursue collaborative
research related to vascular procedures [35] . 
As has been demonstrated, the impact of the COVID pan-
demic on each registry within VASCUNET and VQI has been
variable, related heavily to the overall prevalence of the virus
in each country, the governmental approach to virus contain-
ment, the burden on clinical operations, and the impact of per-
sonnel who collect data within each registry. 
Although ICVR has not yet collected harmonized variables
across VASCUNET and VQI, the extensive data collection by
both the VQI and numerous registries within VASCUNET will
allow for future collaborative projects, similar to what has
been reported previously [36 ,37] . Given the impact of COVID-
19 on vascular practice and the high frequency of vascular
complications from the virus, the value of worldwide data col-
lection cannot be overstated. The rapid addition and harmo-
nization of variables that has occurred during the pandemic is
an exercise that will serve all ICVR-participating registries in
the future. Data collection for unexpected and infrequent de-
vice failures of this nature in international real-world practice
will certainly benefit from the mechanisms that have been es-
tablished within ICVR related to the pandemic [38] . 
10. Summary 
Registry data has always played an important role in provid-
ing real-world data driving clinical practice through quality
improvement. It has now become increasingly evident that
real-world evidence plays an important role in evaluating
real-world problems dynamically. In 2019, the vascular com-
munity was disrupted by the Paclitaxel controversy. Registry
data helped us better understand the impact of Paclitaxel de-
vices on long-term mortality (Germanvasc, VQI, SwedePAD
[Swedish Drug-elution Trial in Peripheral Arterial Disease],
Australia/New Zealand, and Spain) [39–42] . In 2020, the vas-
cular community was disrupted by the COVID-19 pandemic.
























































































Again, real-world evidence from registries is helping us better
understand the impact and how we should adapt using up-to-
date information. Undoubtedly, there will be future events or
pandemics where registry data and real-world evidence will
help us to better respond in a timely manner. We must pre-
pare our clinical and administrative registries to be adaptable,
responsive, and use active surveillance monitoring to identify
signal detection or address future unknown events. As a first
important step, the responsible consortia implemented corre-
sponding codes to identify patients with positive SARS-CoV-
2 infection in registry and administrative data. This empha-
sizes that events with enough impact can lead to changes in
an often-rigid environment. The vascular community would
be well advised to use the momentum noted and discuss the
implementation of unique device identifiers into administra-
tive data to be prepared for future tasks and challenges. 
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